These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3444799)

  • 61. Acquired neonatal thyroid disease due to TSH receptor antibodies in breast milk.
    Törnhage CJ; Grankvist K
    J Pediatr Endocrinol Metab; 2006 Jun; 19(6):787-94. PubMed ID: 16886586
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Crucial role of serum human chorionic gonadotropin for the aggravation of thyrotoxicosis in early pregnancy in Graves' disease.
    Tamaki H; Itoh E; Kaneda T; Asahi K; Mitsuda N; Tanizawa O; Amino N
    Thyroid; 1993; 3(3):189-93. PubMed ID: 8257857
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Maternal Thyrotropin Receptor Antibody Concentration and the Risk of Fetal and Neonatal Thyrotoxicosis: A Systematic Review.
    van Dijk MM; Smits IH; Fliers E; Bisschop PH
    Thyroid; 2018 Feb; 28(2):257-264. PubMed ID: 29325496
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease.
    Feldt-Rasmussen U; Schleusener H; Carayon P
    J Clin Endocrinol Metab; 1994 Jan; 78(1):98-102. PubMed ID: 8288723
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Partial prediction of postpartum Graves' thyrotoxicosis by sensitive bioassay for thyroid-stimulating antibody measured in early pregnancy.
    Ide A; Amino N; Nishihara E; Kudo T; Ito M; Kimura Y; Tatsumi N; Yamazaki M; Miyauchi A
    Endocr J; 2016 Oct; 63(10):929-932. PubMed ID: 27432817
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Early prediction of hypothyroidism following 131I treatment for Graves' disease.
    Wilson R; McKillop JH; Black E; Jenkins C; Thomson JA
    Eur J Nucl Med; 1988; 14(4):180-3. PubMed ID: 3169054
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bridge Technology with TSH Receptor Chimera for Sensitive Direct Detection of TSH Receptor Antibodies Causing Graves' Disease: Analytical and Clinical Evaluation.
    Frank CU; Braeth S; Dietrich JW; Wanjura D; Loos U
    Horm Metab Res; 2015 Nov; 47(12):880-8. PubMed ID: 26079838
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Performance of a third-generation TSH-receptor antibody in a UK clinic.
    Theodoraki A; Jones G; Parker J; Woolman E; Martin N; Perera S; Thomas M; Bunn C; Khoo B; Bouloux PM; Vanderpump MP
    Clin Endocrinol (Oxf); 2011 Jul; 75(1):127-33. PubMed ID: 21521291
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Failure of the TRH test to predict the clinical course of patients in remission after antithyroid drug therapy for Graves' disease.
    Irvine WJ; Gray RS; Toft AD; Seth J; Cameron EH
    Acta Endocrinol (Copenh); 1979 Jan; 90(1):18-22. PubMed ID: 104514
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A hyperthyroid patient with measurable thyroid-stimulating hormone concentration - a trap for the unwary.
    Tan M; Tan F; Hawkins R; Cheah WK; Mukherjee JJ
    Ann Acad Med Singap; 2006 Jul; 35(7):500-3. PubMed ID: 16902728
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prediction of relapse in hyperthyroid Graves' disease.
    McGregor AM; Smith BR; Hall R; Petersen MM; Miller M; Dewar PJ
    Lancet; 1980 May; 1(8178):1101-3. PubMed ID: 6103438
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunoradiometric assay of serum thyroid stimulating hormone (TSH) as a first-line test in a mixed hospital population.
    Rønnov-Jessen D; Skov L; Faber J
    Clin Chim Acta; 1987 Sep; 168(1):13-7. PubMed ID: 3665101
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis.
    Perdomo CM; García-Goñi M; Sancho L; J Paricio J; Lozano MD; de la Higuera M; Currás M; Arbizu J; Galofré JC
    Clin Endocrinol (Oxf); 2021 Mar; 94(3):466-472. PubMed ID: 32767493
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Higher than conventional doses of carbimazole in the treatment of thyrotoxicosis.
    O'Malley BP; Rosenthal FD; Northover BJ; Jennings PE; Woods KL
    Clin Endocrinol (Oxf); 1988 Sep; 29(3):281-8. PubMed ID: 3251667
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Laboratory based study of undetectable thyroid stimulating hormone.
    Pollock MA; Jones A
    J Clin Pathol; 1989 Dec; 42(12):1237-40. PubMed ID: 2613915
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A cautionary tale: inappropriate drug treatment after false-positive diagnosis of thyrotoxicosis.
    Stubbs PJ; Oppert SA; Collinson PO
    Clin Chem; 1990 Jul; 36(7):1381-3. PubMed ID: 2372960
    [No Abstract]   [Full Text] [Related]  

  • 77. Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis.
    Wood CL; Cole M; Donaldson M; Dunger DB; Wood R; Morrison N; Matthews JNS; Pearce SHS; Cheetham TD
    Eur J Endocrinol; 2020 Dec; 183(6):637-645. PubMed ID: 33107439
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Follow-up of a case of subacute thyroiditis with uncommon thyroid (99m)Tc uptake.
    Zhang Z; Li C
    Arq Bras Endocrinol Metabol; 2013 Nov; 57(8):659-62. PubMed ID: 24343637
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inflammatory myopathy in thyrotoxicosis.
    Hardiman O; Molloy F; Brett F; Farrell M
    Neurology; 1997 Feb; 48(2):339-41. PubMed ID: 9040717
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Carbimazole--resistant thyrotoxicosis.
    Corvilain B; Schinohoritis P
    Postgrad Med J; 1997 Oct; 73(864):686. PubMed ID: 9497996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.